A new study published in Translational Psychiatry, concluded CBD could represent “a completely new mechanism in the treatment of schizophrenia.” The Phase II study was randomized, controlled, and double-blind.
Forty two “acutely exacerbated schizophrenic patients” were randomly assigned to a three-week treatment of CBD or a standard antipsychotic medication (amisulpride). In progressive steps, the patients received up to 800 mg of CBD a day, delivered in four smaller doses. The researchers discovered both “cannabidiol or amisulpride treatment showed significant clinical improvement”. In the data, there were no significant differences between the two medications.
See the original article at Rx Leaf